Cytosorbents Corporation (CTSO) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Cytosorbents Corporation.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.752 -- 00:00:06.933 Good afternoon, ladies and gentlemen, and welcome to Cytosorbents' second quarter 00:00:06.933 -- 00:00:12.474 earnings call conference call. At this time, all lines are in listen-only mode. 00:00:12.474 -- 00:00:17.075 Following the presentation, we will conduct a question-and-answer session. 00:00:17.075 -- 00:00:22.156 If at any time during this call, you require immediate assistance, please press star 00:00:22.156 -- 00:00:27.617 zero for the operator. This call is being recorded on Thursday, August 00:00:27.617 -- 00:00:29.777 6, 2026. 00:00:30.351 -- 00:00:33.493 I would now like to turn the conference over to Pete Mariani. 00:00:33.493 -- 00:00:36.033 Please go ahead. 00:00:36.915 -- 00:00:39.857 Thank you, Matthew, and good afternoon, everyone. 00:00:39.857 -- 00:00:44.039 Welcome to Cytosorbents' second quarter 2026 conference call. 00:00:44.039 -- 00:00:48.281 Joining me today is Dr. Phillip Chan, our chief executive officer, Dr. 00:00:48.281 -- 00:00:51.864 Micah Deliargyris, our chief medical officer. 00:00:51.864 -- 00:00:56.386 During today's call, we will have an overview presentation covering the operating and 00:00:56.386 -- 00:01:00.131 financial highlights for the second quarter of 2026. 00:01:00.131 -- 00:01:05.214 and a review of our four key drivers of value creation, including a regulatory 00:01:05.214 -- 00:01:11.018 update on our process to obtain U.S. marketing approval for DrugSorb ATR. 00:01:11.018 -- 00:01:15.922 Following the presentation, we will open the lines to analysts for questions. 00:01:15.922 -- 00:01:20.545 Before I turn the call over to Phil, I'd like to remind listeners that during the call, 00:01:20.545 -- 00:01:25.728 management's prepared remarks may contain forward-looking statements, w...